Olema Pharmaceuticals amends bylaws to update stockholder nomination procedures

Olema Pharmaceuticals, Inc.

Board approved amended and restated bylaws effective December 15, 2022.
Revisions address Rule 14a-19 universal proxy rules and update director nomination information requirements.
Updated provisions on conduct of stockholder meetings and setting date, time, place.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Olema Pharmaceuticals, Inc.: Amended and restated bylaws to update procedures for stockholder nominations regarding Rule 14a-19, update information requirements for director nominations and other business proposals, and update provisions for stockholder meetings (effective 2022-12-15).

Change: bylaw amendment
Effective: 2022-12-15

Exact text from the filing

On December 15, 2022, the Board of Directors (the “ Board ”) of Olema Pharmaceuticals, Inc. (the “ Company ”) approved the amendment and restatement of the Bylaws of the Company (the “ Amended and Restated Bylaws ”). The Amended and Restated Bylaws are effective as of December 15, 2022.

View on SEC.gov

Browse all governance changes →

Olema Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-22-018762

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.